In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Onconova Therapeutics Inc. (NASDAQ:ONTX) reported that Sabby Capital has picked up 702,896 of common stock as of 2017-05-01.
The acquisition brings the aggregate amount owned by Sabby Capital to a total of 702,896 representing less than 7.61% stake in the company.
For those not familiar with the company, Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company’s lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.
A glance at Onconova Therapeutics Inc. (NASDAQ:ONTX) key stats reveals a current market capitalization of 22.72 Million based on 9.24 Million shares outstanding and a price at last close of $2.35 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-04-26, Bienen picked up 3,810 at a purchase price of $2.10. This brings their total holding to 12,724 as of the date of the filing.
On the sell side, the most recent transaction saw Kumar unload 20,000 shares at a sale price of 15.11. This brings their total holding to 276,500.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Onconova Therapeutics Inc. (NASDAQ:ONTX) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
